NCT01933815 2023-02-22
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Cortice Biosciences, Inc.
Phase 1/2 Suspended
Clinical Trials
6 trialsNCT02047214 2018-01-31
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
Cortice Biosciences, Inc.
Phase 2 Terminated
NCT00479635 2014-01-22
A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
Cortice Biosciences, Inc.
Phase 2 Terminated
NCT00553813 2014-01-22
A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer
Cortice Biosciences, Inc.
Phase 2 Terminated
NCT00113724 2009-06-04
Study of TPI 287 in Patients With Advanced Malignancies
Cortice Biosciences, Inc.
Phase 1 Completed
NCT00256191 2007-10-15
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies
Cortice Biosciences, Inc.
Phase 1 Completed